Identification of genetic markers that predicts adverse effects of new melanoma therapies
Not Applicable
- Conditions
- malignant melanoma
- Registration Number
- JPRN-UMIN000028523
- Lead Sponsor
- Kyoto University
- Brief Summary
Our analysis showed that no KIR gene was associated with a response to nivolumab. The KIR/KIR-ligand combination did not correlate with a response to nivolumab. KIR genes were not predictive of experiencing adverse events of grade 2 or greater. We conclude that the KIR genotype or KIR/KIR-ligand genotype do not show predictive value in melanoma patients receiving nivolumab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 112
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are followed for less than 3 months after the initiation of the therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse effect that result from new melanoma therapy
- Secondary Outcome Measures
Name Time Method